New technology for delivering drugs directly to the brain for Alzheimer's and related dementias
Official title: Targeted Cerebral Spinal Fluid (CSF) Drug Delivery - Enclear Precision System
Funded at Enclear Therapies, INC. · NIH-11204746 · Data updated 2026-11-12
This study is exploring a new way to deliver medications directly to the brain for people with Alzheimer's disease and Frontotemporal Dementia, using advanced technology to make treatments more effective.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Enclear Therapies, INC. NIH-funded |
| Lab location | 1 site (Newburyport, UNITED STATES) |
| Project start | January 1, 2024 |
| Project end | December 31, 2025 |
| Funding year | 2025 |
| Award (this year) | $2,977,025 |
| NIH project number | 4R44NS135792-02 |
| Project ID | NIH-11204746 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with Alzheimer's disease or Frontotemporal Dementia who may benefit from targeted drug delivery therapies.
✕Less likely to help
Patients with other forms of dementia or neurological disorders unrelated to Alzheimer's or FTD may not receive benefit from this research.
What this research studies
This research focuses on developing a novel system for targeted delivery of drugs to the brain, specifically for conditions like Alzheimer's disease and Frontotemporal Dementia (FTD). The approach combines advanced drug delivery technology with gene therapy techniques to enhance the effectiveness of treatments. By utilizing a system that precisely controls the flow of cerebrospinal fluid (CSF), the researchers aim to improve the distribution of therapeutic agents directly to affected neurons. This innovative method addresses the challenges of traditional gene therapies that often fail due to inadequate brain penetration.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for Alzheimer's disease and related dementias, potentially improving patient outcomes and quality of life.
How similar studies have gone: While targeted drug delivery systems are being explored, this specific approach combining CSF flow control with gene therapy for Alzheimer's and FTD is relatively novel and has not been extensively tested in prior studies.
Where this research is happening
-
Enclear Therapies, INC.
Newburyport, United States Active
Researchers
- Principal investigator: Glicksman, Marcie a — Enclear Therapies, INC.
- Study coordinator: Glicksman, Marcie a
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.